Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05364307 | Recruiting | Alzheimer Disease

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Sponsor:

Global Alzheimer's Platform Foundation

Brief Summary:

Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.

Condition or disease

Alzheimer Disease

Mild Cognitive Impairment

Memory Loss

Memory Disorders

Memory Impairment

Intervention/treatment

Prescreener database

Study Type : Observational
Estimated Enrollment : 3000 participants
Official Title : Identification of Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) Patients With a High Probability of Meeting Eligibility Criteria for a Therapeutic Alzheimer's Disease Clinical Trial (APHELEIA)
Actual Study Start Date : June 13, 2022
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : December 2024

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 50 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • 1. Participants and/or a legally authorized representative (LAR) must provide signed and dated informed consent and authorization to use personal health information in accordance with local and national guidance and regulations;
  • 2. Male or female 50 to 90 years of age (inclusive) at the time of consent;
  • 3. Participants must have a Mini-Mental State Exam (MMSE) score of 20 to 28 inclusive;
  • 4. Progressive cognitive complaints must be reported by participant or caregiver;
  • 5. Participants must be willing to comply with all procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;
  • 6. Fluency in the language of the tests used at the site;
  • 7. Participants must be interested in participating in clinical research.
Exclusion Criteria
  • 1. Participants who, in the opinion of the Investigator, have serious or unstable medical conditions that would prohibit their completion of all prescreening procedures and data collection;
  • 2. Participants who are currently enrolled in another clinical study.
  • 3. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;
  • 4. Participants who have reported or have a known negative amyloid PET scan in the past 24 months;
  • 5. Participants with history of stroke within 6 months of prescreening;
  • 6. Participants with an uncontrolled seizure disorder, unexplained blackouts, OR history of a seizure within 6 months (subjects with a history of pediatric febrile seizure, benign rolandic epilepsy may participate);
  • 7. Participants with a history or evidence of a malignancy within the 2 years prior to prescreening. Subjects with indolent malignancies (e.g., basal cell carcinoma or squamous cell carcinoma) or malignancies considered to be cured and not actively treated with anti-cancer therapy or radiotherapy are permitted to enroll;
  • 8. Participants with known or suspected alcohol or drug abuse or dependence within 2 years of prescreening;
  • 9. Participants with a reported suicidal attempt within 2 years of prescreening), or any unstable psychiatric symptoms (e.g., uncontrolled depression);
  • 10. Participants who have participated in a clinical trial of any potential disease modifying AD treatment and received active drug within 6 months prior to prescreening;
  • 11. Participants who have any neurological disorder affecting the central nervous system, other than AD, that may be contributing to cognitive impairment (e.g., Parkinson's disease, other dementias, multiple concussions or seizures) as deemed significant by the Investigator;
  • 12. Participants with known history of hepatitis C virus, hepatitis B virus, human immunodeficiency virus (HIV) or other immunodeficiencies;
  • 13. Participants that have previously been consented to this protocol;
  • 14. Participants with a hypersensitivity to mAb treatments, protein derived from a mAb, or immunoglobulin therapy;
  • 15. Participants with allergies to diphenhydramine, epinephrine, and methylprednisolone;
  • 16. Participants who are direct employees or family members of direct employees of the participating investigators' sites;
  • 17. Participants who are direct employees of the Sponsor;
  • 18. Participants who, in the opinion of the Investigator, are unable to complete cognitive testing due to inadequate visual or auditory acuity.
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

Location Details

Please Choose a site

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Recruiting

United States, California

Pacific Research Network

San Diego, California, United States, 92103

Recruiting

United States, California

Syrentis Clinical Research

Santa Anna, California, United States, 92705

Recruiting

United States, Florida

Visionary Investigator's Network

Aventura, florida, United States, 33180

Recruiting

United States, Florida

Charter Research

Lady Lake, florida, United States, 32159

Recruiting

United States, Florida

JEM Research Institute

Lake Worth, florida, United States, 33462

Recruiting

United States, Florida

ClinCloud, LLC

Maitland, florida, United States, 32751

Recruiting

United States, Florida

K2 Medical Research

Maitland, florida, United States, 32751

Recruiting

United States, Florida

Merritt Island Medical Research

Merritt Island, florida, United States, 32952

Recruiting

United States, Florida

Renstar Medical Research

Ocala, florida, United States, 34471

Recruiting

United States, Florida

ClinCloud, LLC

Viera, florida, United States, 32940

Recruiting

United States, Florida

Premiere Research Institute at Palm Beach Neurology

West Palm Beach, florida, United States, 33407

Recruiting

United States, Florida

Conquest Research

Winter Park, florida, United States, 32789

Recruiting

United States, Florida

Charter Research

Winter Park, florida, United States, 32792

Recruiting

United States, Georgia

iResearch

Decatur, Georgia, United States, 30030

Recruiting

United States, road cancer

Quest Research Institute

Farmington Hills, road cancer, United States, 48334

Not yet recruiting

United States, Oklahoma

IPS Research

Oklahoma City, Oklahoma, United States, 73106

Recruiting

United States, Texas

Clinical Trials of Texas

Saint Anthony, Texas, United States, 78229

Recruiting

United States, Virginia

Re:Cognition Health

Fairfax, Virginia, United States, 22031

Not yet recruiting

Canada, British Columbia

OCT Research

Kelowna, British Columbia, Canada, V1V 1Z9